Foresite Capital Management IV
Latest statistics and disclosures from Foresite Capital Management IV's latest quarterly 13F-HR filing:
- Top 5 stock holdings are KNTE, Lyell Immunopharma, PHVS, ACRS, Quantum Si, and represent 83.27% of Foresite Capital Management IV's stock portfolio.
- Added to shares of these 3 stocks: Lyell Immunopharma (+$216M), Quantum Si (+$55M), Tempest Therapeutics.
- Started 3 new stock positions in Lyell Immunopharma, Quantum Si, Tempest Therapeutics.
- Reduced shares in these 7 stocks: KROS (-$85M), ALXO (-$58M), RLAY (-$58M), CYTK (-$6.7M), Therapeutics Acquisition Cor, OLMA, NRIX.
- Sold out of its positions in ALXO, KROS, Therapeutics Acquisition Cor.
- Foresite Capital Management IV was a net buyer of stock by $59M.
- Foresite Capital Management IV has $740M in assets under management (AUM), dropping by -11.38%.
- Central Index Key (CIK): 0001704132
Tip: Access up to 7 years of quarterly data
Positions held by Foresite Capital Management IV consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Foresite Capital Management IV
Companies in the Foresite Capital Management IV portfolio as of the June 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Kinnate Biopharma (KNTE) | 30.4 | $225M | 9.7M | 23.28 | ||
| Lyell Immunopharma | 29.2 | $216M | NEW | 13M | 16.24 | |
| Pharvaris N V (PHVS) | 8.2 | $61M | 3.3M | 18.63 | ||
| Aclaris Therapeutics (ACRS) | 8.1 | $60M | 3.4M | 17.56 | ||
| Quantum-Si Incorporated Com Cl A | 7.4 | $55M | NEW | 4.5M | 12.26 | |
| Kura Oncology (KURA) | 5.2 | $39M | 1.8M | 20.85 | ||
| Nurix Therapeutics (NRIX) | 4.3 | $32M | -2% | 1.2M | 26.53 | |
| Relay Therapeutics (RLAY) | 2.8 | $20M | -73% | 556k | 36.59 | |
| Cytokinetics (CYTK) | 1.5 | $11M | -38% | 545k | 19.79 | |
| Olema Pharmaceuticals (OLMA) | 1.3 | $9.6M | -12% | 342k | 27.98 | |
| Cymabay Therapeutics (CBAY) | 1.1 | $7.8M | 1.8M | 4.36 | ||
| Decibel Therapeutics (DBTX) | 0.3 | $2.6M | 298k | 8.60 | ||
| Tempest Therapeutics | 0.3 | $2.1M | NEW | 190k | 11.18 |
Past Filings by Foresite Capital Management IV
SEC 13F filings are viewable for Foresite Capital Management IV going back to 2017
- Foresite Capital Management IV 2021 Q2 filed Aug. 16, 2021
- Foresite Capital Management IV 2021 Q1 filed May 17, 2021
- Foresite Capital Management IV 2020 Q4 filed Feb. 16, 2021
- Foresite Capital Management IV 2020 Q3 filed Nov. 13, 2020
- Foresite Capital Management IV 2020 Q2 filed Aug. 13, 2020
- Foresite Capital Management IV 2020 Q1 restated filed May 28, 2020
- Foresite Capital Management IV 2020 Q1 filed May 14, 2020
- Foresite Capital Management IV 2019 Q4 filed Feb. 14, 2020
- Foresite Capital Management IV 2019 Q3 filed Nov. 13, 2019
- Foresite Capital Management IV 2019 Q2 filed Aug. 13, 2019
- Foresite Capital Management IV 2019 Q1 filed May 14, 2019
- Foresite Capital Management IV 2018 Q4 filed Feb. 13, 2019
- Foresite Capital Management IV 2018 Q3 filed Nov. 13, 2018
- Foresite Capital Management IV 2018 Q2 filed Aug. 14, 2018
- Foresite Capital Management IV 2018 Q1 filed May 15, 2018
- Foresite Capital Management IV 2017 Q4 filed Feb. 13, 2018